Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decanal SCHEMBL8208889 | 0.94 | TSHR (0.44) | ALOX15TSHRALDH1A1USP2MAPT | |
| SCHEMBL17242080 | 0.81 | ALOX15 (0.55) | ALOX15TSHRALDH1A1USP2HPGD | |
| SCHEMBL29785 | 0.81 | ALOX15 (0.55) | ALOX15TSHRALDH1A1USP2HPGD | |
| SCHEMBL17967768 | 0.81 | ALOX15 (0.55) | ALOX15TSHRALDH1A1USP2HPGD | |
| SCHEMBL28249306 | 0.80 | TSHR (0.42) | ALOX15TSHRALDH1A1USP2MAPT | |
| SCHEMBL9853371 | 0.78 | ALOX15 (0.44) | ALOX15TSHRALDH1A1 | |
| SCHEMBL9853369 | 0.78 | ALOX15 (0.44) | ALOX15TSHRALDH1A1 | |
| Undecanal SCHEMBL8210493 | 0.78 | TSHR (0.53) | TSHRALDH1A1USP2MAPTCYP3A4 | |
| SCHEMBL23019164 | 0.77 | TSHR (0.44) | TSHRALDH1A1USP2MAPTCYP3A4 | |
| SCHEMBL3126461 | 0.77 | TSHR (0.44) | TSHRALDH1A1USP2MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010005711-A1 | Perfume compositions comprising 4,8-dimethyl-3,7-nonadien-2-one | SYMRISE GMBH & CO. KG (DE) | 2001-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005711-A1 | Perfume compositions comprising 4,8-dimethyl-3,7-nonadien-2-one | DEK, DPM1, DEGS1 | ALOX15 868/4885TSHR 4800/4885ALDH1A1 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.